Reduced symptom burden, faster recovery with NMV/r vs placebo
13 Dec 2025
Treatment with nirmatrelvir/ritonavir (NMV/r) reduced both the duration and severity of COVID-19 symptoms, based on patients’ overall perception of their symptom burden, and facilitated a faster return to normal health and activities, as demonstrated in a recent exploratory analysis.
Resources
Reduced symptom burden, faster recovery with NMV/r vs placebo
Reduced symptom burden, faster recovery with NMV/r vs placebo